Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, expects to achieve important milestones in the year ahead. The company’s proprietary i/Blue Imaging System is designed to significantly enhance surgeons’ ability to visualize and remove cancer cells using blue light by combining advanced optics and light sensors with a contrast imaging agent. The system’s key feature is its adaptability to almost any scope already in use by hospitals and surgical centers. Despite the challenges of 2020, Imagin was able to transition its product from the development stage to manufacturing, contracting with FDA registered and ISO 13485:2016-certified manufacturer Lighthouse Imaging. The contract will assist to propel Imagin toward completion of its final pre-production stage and finalize test parameters that meet exacting FDA requirements for live-use surgical imaging equipment. “Our relationship with Lighthouse Imaging marks a new stage in the company’s progress,” Imagin President and CEO Jim Hutchens stated in a recent update. “We anticipate 2021 to be a breakout year with emphasis on manufacturing and the FDA process.”
To view the full article, visit https://ibn.fm/3dZUz
About Imagin Medical
Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The company believes its first product, the i/Blue(TM) Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The company’s initial focus is bladder cancer. For more information about the company, visit www.ImaginMedical.com.
NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork